Update on third-generation EGFR tyrosine kinase inhibitors.

@article{Gray2014UpdateOT,
  title={Update on third-generation EGFR tyrosine kinase inhibitors.},
  author={Jhanelle Gray and Eric B. Haura},
  journal={Translational lung cancer research},
  year={2014},
  volume={3 6},
  pages={360-2}
}
Transl Lung Cancer Res 2014;3(6):360-362 www.tlcr.org Among patients with non-small cell lung cancer (NSCLC), EGFR mutations, 90% of which present as an exon 19 deletion or exon 21 point mutation L858R, have been detected in Western and Asian populations at a rate of ~15% and ~40%, respectively. To date, numerous trials have established the efficacy and toxicity profile of singleagent oral EGFR-tyrosine kinase inhibitor (TKI) therapies for EGFR-TKI-naïve NSCLC patients harboring EGFR mutations… CONTINUE READING

References

Publications referenced by this paper.
Showing 1-10 of 10 references

First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR (activating and T790M)

  • LV Sequist, J-C Soria, SM Gadgeel
  • J Clin Oncol
  • 2014
Highly Influential
11 Excerpts

Activity of afatinib/ cetuximab in patients (pts) with EGFR mutant non-small cell lung cancer (NSCLC) and acquired resistance (AR) to EGFR inhibitors

  • YY Janjigian, EF Smit, L Horn
  • Ann Oncol
  • 2012
1 Excerpt

Similar Papers

Loading similar papers…